|
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin Clinical research trials and Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin. Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin clinical trial. Subjects frequently obtain the most expert healthcare possible for their Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin  Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
For Condition: adenocarcinoma of unknown primary,newly diagnosed carcinoma of unknown primary
Status: No longer recruiting
Sponsor(s): Academisch Ziekenhuis Maastricht ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for cancer of unknown primary origin. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating patients with cancer of unknown primary origin.
Details: OBJECTIVES: - Compare the overall survival after treatment with paclitaxel, carboplatin, and etoposide and after treatment with fluorouracil and leucovorin calcium in patients with adenocarcinoma of unknown primary. - Compare the response rates, progression free survival, toxicity profile, and quality of life between the two regimens in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified by center and presence or absence of liver metastases. Patients are randomly assigned to one of two treatment arms. - Arm I: Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1, and oral etoposide on days 1-10. Treatment is repeated every 3 weeks for up to four courses. - Arm II: Patients receive leucovorin calcium IV over 2 hours followed by fluorouracil IV over 24 hours weekly for 6 weeks. Treatment is repeated every 7 weeks for up to two courses. Patients are followed every 3 months after treatment for 1 year or until death. Quality of life questionnaires are completed at each follow-up. PROJECTED ACCRUAL: Approximately 120-140 patients will be accrued for this study within 3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of any differentiation grade - Excludes the following "treatable" conditions: - Axillary node involvement - Peritonitis carcinomatosis - Blastic bone metastases and/or elevated PSA - Squamous cell cancer with cervical or inguinal presentation - Poorly differentiated carcinoma - Neuroendocrine tumors OR - Tumors located in the mediastinum, retroperitoneum, or nodes - At least one measurable metastatic site - No brain or meningeal metastases PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-2 Hematopoietic: - Leukocyte count at least 4,000/mm3 - Thrombocyte count at least 100,000/mm3 Hepatic: - Bilirubin less than 1.4 mg/dL - AST and ALT less than 3 times upper limit of normal - No cirrhosis of the liver Renal: - Creatinine less than 1.7 mg/dL Cardiovascular: - At least 3 months since myocardial infarction - No congestive heart failure, tachydysrhythmia, or unstable angina pectoris Other: - Not pregnant or nursing - Negative pregnancy test - No active infection - No other serious illness or medical condition - No current or prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy (no greater than 25% of bone marrow) Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
R.L.Jansen, Study Chair, Academisch Ziekenhuis Maastricht
Academisch Ziekenhuis Maastricht
Maastricht, , 6202 AZ
Netherlands
St. Elisabeth Ziekenhuis
Tilburg, , 5022 GC
Netherlands
Additional Information:
Study ID Numbers: CDR0000066622; DUT-KWF-CKVO-9801,EU-98023
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003558
Other Adenocarcinoma Of Unknown Primary Studies:
1. Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
2. Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
3. Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
4. Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
5. Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
Related Studies:
Other adenocarcinoma of unknown primary Clinical Trials
Other Clinical Trials
Other Tilburg Clinical Trials
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
|
|
|
|
|
|
|
|
